Pandian Saravanakumar, Jeevanesan Vinoth, Ponnusamy Chandrasekar, Natesan Subramanian
Laboratory for Lipid Based Systems, Department of Pharmaceutical Technology, BIT Campus, Anna University, Tiruchirappalli 620 024, Tamil Nadu, India.
IET Nanobiotechnol. 2017 Feb;11(1):32-39. doi: 10.1049/iet-nbt.2016.0069.
The objective of this study is to develop resveratrol (RES) loaded polyethylene glycols (PEGs) modified chitosan (CS) nanoparticles (NPs) by ionic gelation method for the treatment of glaucoma. While increasing the concentration of PEG, the particle size and polydispersity index of the formulations increased. Entrapment efficiency and RES loading (RL) of NPs decreased while increasing PEG concentration. The in vitro release of NPs showed an initial burst release of RES (45%) followed by controlled release. Osmolality of formulations revealed that the prepared NPs were iso-osmolar with the tear. Ocular tolerance of the NPs was evaluated using hen's egg test on the chorioallantoic membrane and it showed that the NPs were non-irritant. RES-loaded PEG-modified CS NPs shows an improved corneal permeation compared with RES dispersion. Fluorescein isothiocyanate loaded CS NPs accumulated on the surface of the cornea but the PEG-modified CS NPs crossed the cornea and reached retinal choroid. RES-loaded PEG-modified CS NPs reduced the intra-ocular pressure (IOP) by 4.3 ± 0.5 mmHg up to 8 h in normotensive rabbits. These results indicate that the developed NPs have efficient delivery of RES to the ocular tissues and reduce the IOP for the treatment of glaucoma.
本研究的目的是通过离子凝胶法制备负载白藜芦醇(RES)的聚乙二醇(PEG)修饰壳聚糖(CS)纳米颗粒(NPs)用于青光眼治疗。随着PEG浓度的增加,制剂的粒径和多分散指数增大。纳米颗粒的包封率和RES载药量(RL)随着PEG浓度的增加而降低。纳米颗粒的体外释放显示RES有一个初始的突释(45%),随后是控释。制剂的渗透压显示所制备的纳米颗粒与泪液等渗。使用鸡胚尿囊膜试验评估纳米颗粒的眼耐受性,结果表明纳米颗粒无刺激性。与RES分散体相比,负载RES的PEG修饰CS纳米颗粒显示出改善的角膜渗透性。负载异硫氰酸荧光素的CS纳米颗粒积聚在角膜表面,但PEG修饰的CS纳米颗粒穿过角膜并到达视网膜脉络膜。在正常血压的兔子中,负载RES的PEG修饰CS纳米颗粒在长达8小时内使眼压(IOP)降低了4.3±0.5 mmHg。这些结果表明,所开发的纳米颗粒能有效地将RES递送至眼组织并降低眼压,可用于青光眼治疗。